Sphingosine kinase 1 is a relevant molecular target in gastric cancer

Anti-Cancer Drugs

Volumn 22, Issue 3, 2011, Pages 245-252

  Fuereder, Thorsten ^a   Hoeflmayer, Doris ^a   Jaeger Lansky, Agnes ^a   Rasin Streden, Doris ^a   Strommer, Sabine ^a   Fisker, Niels ^b   Hansen, Bo J ^b   Crevenna, Richard ^a   Wacheck, Volker ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Santaris Pharma AS   (Denmark)

Author keywords

gastric cancer; locked nucleic acid antisense oligonucleotides; sphingosine kinase 1; xenografts

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; LOCKED NUCLEIC ACID; MESSENGER RNA; SPHINGOSINE KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIZATION; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); STOMACH NEOPLASMS; TRANSFECTION;

EID: 79951587631     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328340bd95     Document Type: Article

References (23)

1. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604-616. (Pubitemid 39025055)
2. Sarkar S, Maceyka M, Hait NC, Paugh SW, Sankala H, Milstien S, et al. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett 2005; 579:5313-5317. (Pubitemid 41395149)
3. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 2002; 1585:114-125. (Pubitemid 36092075)
4. Kim JW, Kim YW, Inagaki Y, Hwang YA, Mitsutake S, Ryu YW, et al. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg Med Chem 2005; 13:3475-3485. (Pubitemid 40545803)
5. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 2002; 1585:193-201. (Pubitemid 36096858)
6. Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEBJ 2006; 20:386-388. (Pubitemid 46671180)
7. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63:5962-5969. (Pubitemid 37187498)
8. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009; 15:1393-1399.
9. Cejka D, Losert D, Wacheck V. Short interfering RNA (siRNA): tool or therapeutic? Clin Sci (Lond) 2006; 110:47-58. (Pubitemid 43059044)
10. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006; 318:596-603. (Pubitemid 44061234)
11. Endo K, Igarashi Y, Nisar M, Zhou QH, Hakomori S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res 1991; 51:1613-1618.
12. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003;270:1628-1644. (Pubitemid 36532522)
13. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-899. (Pubitemid 351550859)
14. Wacheck V, Cejka D, Sieghart W, Losert D, Strommer S, Crevenna R, et al. Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther 2006; 5:1348-1354. (Pubitemid 44772262)
15. Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, et al. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med 2001; 79:587-593. (Pubitemid 32938387)
16. Tomg QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH, et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 2005; 12:509-514. (Pubitemid 40629341)
17. Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control ofgastric cancergrowth in vivo. Cancer Biol Ther 2008; 7:1377-1385.
18. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 2009; 69:6915-6923.
19. Allum WH, Griffin SM, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 2002; 50 (Suppl 5):v1-v23.
20. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006; 20:633-649. (Pubitemid 44391336)
21. Taha TA, Kitatani K, El-Alwani M, Bielawski J, Hannun YA, Obeid LM. Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J 2006;20:482-484. (Pubitemid 46671223)
22. Jepsen JS, Sorensen MD, Wengel J. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides 2004; 14:130-146. (Pubitemid 38987382)
23. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008; 36:4158-4171. (Pubitemid 351984831)